ALEMTUZUMAB-CONDITIONED HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION CONFERS EXCELLENT SURVIVAL WITH LIMITED GVHD IN FANCONI ANEMIA (EBMT 2026) - Feb 7, 2026 - Abstract #OS20-07; Pres time: Mar 25, 2026; 01:24 PM - 01:33 PM; Location: N107; "We present outcomes for patients with FA who underwent haploidentical transplantation with alemtuzumab-based conditioning and GVHD prophylaxis with a modified post-transplant cyclophosphamide (PTCY)...All subjects received bone marrow from haploidentical donors and conditioning with Fludarabine 150mg/m², Total Body Irradiation (TBI) 200cGy, and Alemtuzumab 0,6-0,7mg/kg. GVHD prophylaxis consisted of PTCY 50-60 mg/kg (total dose), Cyclosporin, and Mycofenolate Mofetil...Patients didn't receive letermovir prophylaxis but were successfully treated with preemptive therapy, with no evidence of CMV disease... The modified haploidentical approach incorporating alemtuzumab and PTCY achieves excellent survival outcomes in FA by decreasing rejection and TRM. The RIC approach minimizes toxicity, but careful consideration of TBI exposure and GVHD-associated malignancy risk remains a concern. The addition of alemtuzumab reduced the incidence and severity of GVHD..."
Acute Graft versus Host Disease • Anemia • Aplastic Anemia • Chronic Graft versus Host Disease • Cytomegalovirus Infection • Graft versus Host Disease • Head and Neck Cancer • Immunology • Infectious Disease • Oral Cancer • Solid Tumor • Transplantation
|
|
Rafaella Muratori1,2; Gisele Loth1,3; Adriana Koliski1; Samantha Nichele1,2; Adriana Mello Rodrigues1,3; Joanna Trennepohl1; Lara Gouvea1; Rebeca Toassa Gomes1; Alberto Cardoso Martins Lima1; Daniela Vandresen Pilonetto1; Ana Paula Azambuja1; Lismeri Wuicik Merfort1; Fernanda Moreira de Lara Benini3; Juliana Bach3; Carolina Martins de Almeida Peixoto3; Polliany Pelegrina3; Cilmara Kuwahara3; Celso Arrais4; Juliana Folloni Fernandes5; Luiz Guilherme Darrigo Jr6; Ricardo Pasquini1; Carmem Bonfim1
|